Anaplastic Large Cell Lymphoma, ALK-Negative Completed Phase 1 / 2 Trials for Everolimus (DB01590)

Also known as: Anaplastic Large Cell Lymphoma, ALK-negative

IndicationStatusPhase
DBCOND0061449 (Anaplastic Large Cell Lymphoma, ALK-Negative)Completed1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01198665RAD001 Combined With CHOP in Newly Diagnosed Peripheral T-cell LymphomasTreatment